TY - JOUR
T1 - Opioid dose-And route-dependent efficacy of oxycodone and heroin vaccines in rats
AU - Raleigh, Michael D.
AU - Laudenbach, Megan
AU - Baruffaldi, Federico
AU - Peterson, Samantha J.
AU - Roslawski, Michaela J.
AU - Birnbaum, Angela K
AU - Carroll, F. Ivy
AU - Runyon, Scott P.
AU - Winston, Scott
AU - Pentel, Paul R
AU - Pravetoni, Marco
N1 - Publisher Copyright:
© 2018 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2018/5
Y1 - 2018/5
N2 - Heroin and oxycodone abuse occurs over a wide range of drug doses and by various routes of administration characterized by differing rates of drug absorption. The current study addressed the efficacy of a heroin vaccine [morphine hapten conjugated to keyhole limpet hemocyanin (M-KLH)] or oxycodone vaccine [oxycodone hapten conjugated to keyhole limpet hemocyanin (OXY-KLH)] for reducing drug distribution to brain after intravenous heroin or oxycodone, or subcutaneous oxycodone. Rats immunized with M-KLH or keyhole limpet hemocyanin (KLH) control received an intravenous bolus dose of 0.26 or 2.6 mg/kg heroin. Vaccination with M-KLH increased retention of heroin and its active metabolites 6-Acetylmorphine (6-AM) and morphine in plasma compared with KLH controls, and reduced total opioid (heroin 1 6-AM 1 morphine) distribution to brain but only at the lower heroin dose. Immunization also protected against respiratory depression at the lower heroin dose. Rats immunized with OXYKLH or KLH control received 0.22 or 2.2 mg/kg oxycodone intravenously, the molar equivalent of the heroin doses. Immunization with OXY-KLH significantly reduced oxycodone distribution to brain after either oxycodone dose, although the magnitude of effect of immunization at the higher oxycodone dose was small (12%). By contrast, vaccination with OXY-KLH was more effective when oxycodone was administered subcutaneously rather than intravenously, reducing oxycodone distribution to brain by 44% after an oxycodone dose of 2.3 mg/kg. Vaccination also reduced oxycodone-induced antinociception. These data suggest that the efficacy of OXY-KLH and M-KLH opioid vaccines is highly dependent upon opioid dose and route of administration.
AB - Heroin and oxycodone abuse occurs over a wide range of drug doses and by various routes of administration characterized by differing rates of drug absorption. The current study addressed the efficacy of a heroin vaccine [morphine hapten conjugated to keyhole limpet hemocyanin (M-KLH)] or oxycodone vaccine [oxycodone hapten conjugated to keyhole limpet hemocyanin (OXY-KLH)] for reducing drug distribution to brain after intravenous heroin or oxycodone, or subcutaneous oxycodone. Rats immunized with M-KLH or keyhole limpet hemocyanin (KLH) control received an intravenous bolus dose of 0.26 or 2.6 mg/kg heroin. Vaccination with M-KLH increased retention of heroin and its active metabolites 6-Acetylmorphine (6-AM) and morphine in plasma compared with KLH controls, and reduced total opioid (heroin 1 6-AM 1 morphine) distribution to brain but only at the lower heroin dose. Immunization also protected against respiratory depression at the lower heroin dose. Rats immunized with OXYKLH or KLH control received 0.22 or 2.2 mg/kg oxycodone intravenously, the molar equivalent of the heroin doses. Immunization with OXY-KLH significantly reduced oxycodone distribution to brain after either oxycodone dose, although the magnitude of effect of immunization at the higher oxycodone dose was small (12%). By contrast, vaccination with OXY-KLH was more effective when oxycodone was administered subcutaneously rather than intravenously, reducing oxycodone distribution to brain by 44% after an oxycodone dose of 2.3 mg/kg. Vaccination also reduced oxycodone-induced antinociception. These data suggest that the efficacy of OXY-KLH and M-KLH opioid vaccines is highly dependent upon opioid dose and route of administration.
UR - http://www.scopus.com/inward/record.url?scp=85044947576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044947576&partnerID=8YFLogxK
U2 - 10.1124/jpet.117.247049
DO - 10.1124/jpet.117.247049
M3 - Article
C2 - 29535156
AN - SCOPUS:85044947576
SN - 0022-3565
VL - 365
SP - 346
EP - 353
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 2
ER -